Leerink Swann Targets Transition @ $21
Polak is gonna like this one I think......
Leerink Swann Targets Transition @ $21 ---OutPerform
Leerink Swann Analyst William Tanner, Ph. D. – Managing Director, Biotechnology https://www.transitiontherapeutics.com/ir/analysts.php
William Tanner joined Leerinck Swann & Company in 2002 as Head of the Biotechnology Equity Research group. Dr. Tanner was previously with SG Cowen Securities Corp., where he served as Managing Director and Biotechnology Analyst. Before joining SG Cowen, he served as Biotechnology Analyst at the former Vector Securities Internationale and at Principal Financial Securities. Prior to his positions in equity research, Dr. Tanner was a Research Associate at Washington University School of Medicine's Centre for Immunology and Department of Pathology. Dr. Tanner received his MBA from the Olin School of Business at Washington University and his Ph.D. in Physiology from Texas A&M University. Dr. Tanner did his post-doctorate work at Monsanto Co. in the department of Molecular Genetics and Mammalian Biology. He was a recipient of the National Research Service Award from the National Institutes of Health and received a Postdoctoral Fellowship at the Juvenile Diabetes Foundation."
Thats right polak.........A PostDoctoral Fellowship @ The Juvenile Diabetes Foundation!! Once we've got the INT Based Technologies Platform partnered this guy will see the value in it. Then guess what happens......
Partnering INT could be closer than some think. Think about it for a minute. First of Two G1 Trials just started 4 days ago. Second starts right after with results expected quickly.
Goes a long ways when you're connected.......small world really.
GPP all & Cheers!!!!!